J&J Bid To Ax US Gov't Blood Cancer Patent Gets March Trial
A bid by a subsidiary of Johnson & Johnson to revoke a U.S. government patent covering a treatment for a rare form of blood cancer will go to trial in March,...To view the full article, register now.
Already a subscriber? Click here to view full article